Drug Trial Radar · NCT04370236
INB03 for the Treatment of Pulmonary Complications From COVID-19
Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
79
Actual
Start
Oct 21, 2020
Primary completion
Oct 13, 2021
Study completion Nov 18, 2021
Sponsor
- Lead sponsor
- Inmune Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether XPro1595 can prevent the progression of respiratory complications in COVID19 patients.
Conditions
- COVID-19
Interventions
INB03Drug
Patients will receive up to two once per week subcutaneous injections of 1mg/kg INB03
PlaceboDrug
Patients will receive up to two once per week subcutaneous injections of Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cochran-Mantel-Haenszel Analysis of Proportion of Patients With Disease ProgressionTime frame: 28 days
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
NEA Baptist
Jonesboro, Arkansas
St. Bernard's
Jonesboro, Arkansas
Jewish Hospital
Louisville, Kentucky
Mississippi Baptist
Kosciusko, Mississippi
Baptist Memorial Hospital-DeSoto
Southard, Missouri
Richmond University Medical Center
Staten Island, New York
Baptist Clinical Research Institute
Memphis, Tennessee
Memorial Hermann
Houston, Texas
Memorial Hermann Southeast
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.